赖氨酰氧化酶样蛋白2对晚期胆道癌患者预后及化疗敏感度的预测价值

Predictive value of lysyl oxidase-like protein 2 in prognosis and chemotherapy sensitivity of patients with advanced biliary tract cancer

目的探讨赖氨酰氧化酶样蛋白2(Lysyl oxidase-like protein 2,LOXL2)对晚期胆道癌患者预后及化疗敏感度的预测价值。方法回顾性分析海军军医大学第三附属医院46例晚期胆道癌患者的临床资料。46例病例均采用了实时定量聚合酶链式反应(Quantitative real-time polymerase chain reaction,qRT-PCR)检测患者癌组织和癌旁组织中LOXL2的mRNA表达,根据LOXL2的mRNA表达中位数将患者分为高表达组和低表达组,采用受试者工作特征(Receiver operating characteristic,ROC)曲线分析LOXL2 mRNA在诊断晚期胆道癌化疗敏感性中的价值;采用生存曲线比较LOXL2 mRNA高表达组和低表达组患者生存率;采用Cox回归分析影响胆道癌患者生存的独立风险因素。结果与癌旁组织比较,晚期胆道癌患者癌组织中LOXL2 mRNA的表达增强(t=14.16,P<0.001)。ROC曲线分析结果显示LOXL2 mRNA能够作为诊断晚期胆道癌化疗敏感性的指标(AUC=0.828,P=0.0001)。生存分析结果显示LOXL2 mRNA高表达组患者的总体生存率显著低于低表达组(P=0.032)。Cox回归分析结果显示,CEA、CA19-9以及LOXL2 mRNA水平是影响胆道癌患者化疗后生存的独立风险因素(P=0.005,P=0.041,P=0.012)。结论LOXL2 mRNA是影响患者生存的独立风险因素,且可以作为预测晚期胆道癌患者化疗预后的指标。

Objective To explore the predictive value of lysyl oxidase-like protein 2(LOXL2)on prognosis and chemotherapy sensitivity in patients with advanced biliary tract cancer.MethodsA retrospective analysis was conducted on the clinical data of 46 patients with advanced biliary tract cancer at the hospital.All 46 cases were performed real-time quantitative polymerase chain reaction(qRT PCR)to detect LOXL2 mRNA expression in cancer tissues and adjacent tissues.According to the median of LOXL2 mRNA expression,thepatients were divided into high expression group and low expression group.The value of LOXL2 mRNA in the diagnosis of chemotherapy sensitivity in advanced biliary cancer was analyzed using receiver operating characteristic(ROC)curves.Survival curves were used to compare the survival ratebetween LOXL2 mRNA high expression group and LOXL2 mRNA low expression group.Cox regression was used toanalysze theindependent risk factors affecting the survival of patients with biliary tractcancer.ResultsCompared with adjacent tissues,the expression of LOXL2 mRNA in cancer tissues of the patients with advanced bile duct cancer was significantly increased(t=14.16,P<0.001).The ROC curve analysis showed that LOXL2 mRNA can be used as an indicator for diagnosing chemotherapy sensitivity in advanced biliary tract cancer(AUC=0.828,P=0.0001).Survival analysis revealed that thepatients with high LOXL2 mRNA expression had significantly lower overall survival rates compared to the low expression group(P=0.032).Cox regression analysis showed that CEA,CA19-9 and LOXL2 mRNA levels were independent risk factors affecting survival after chemotherapy in biliary tract cancer patients(P=0.005,P=0.041,P=0.012).ConclusionLOXL2 mRNA is an independent risk factor affecting patient survival and can be used as a predictor of chemotherapy prognosis in patients with advanced biliary cancer.